

# Protein**Reviews**

Series Editor **M. Zouhair Atassi**

---

Volume 6:

## **Protein Misfolding, Aggregation, and Conformational Diseases**

### **Part B: Molecular Mechanisms of Conformational Diseases**

Edited by **Vladimir N. Uversky** and  
**Anthony Fink**

# **Protein Misfolding, Aggregation, and Conformational Diseases**

# PROTEIN REVIEWS

Editorial Board:

**EDITOR-IN-CHIEF:** M. ZOUHAIR ATASSI, *Baylor College of Medicine, Houston, Texas*

**EDITORIAL BOARD:** LAWRENCE J. BERLINER, *University of Denver, Denver, Colorado*  
ROWEN JUI-YOA CHANG, *University of Texas, Houston, Texas*  
HANS JÖRNVALL, *Karolinska Institutet, Stockholm, Sweden*  
GEORGE L. KENYON, *University of Michigan, Ann Arbor, Michigan*  
BRIGITTE WITTMAN-LIEBOLD, *Wittman Institute of Technology and  
Analysis, Tetlow, Germany*

---

Recent Volumes in this Series

VIRAL MEMBRANE PROTEINS: STRUCTURE, FUNCTION, AND DRUG DESIGN  
Edited by Wolfgang B. Fischer

THE p53 TUMOR SUPPRESSOR PATHWAY AND CANCER  
Edited by Gerard P. Zambetti

PROTEOMICS AND PROTEIN-PROTEIN INTERACTIONS: BIOLOGY, CHEMISTRY,  
BIOINFORMATICS, AND DRUG DESIGN  
Edited by Gabriel Waksman

PROTEIN MISFOLDING, AGGREGATION AND CONFORMATIONAL DISEASES  
PART A: PROTEIN AGGREGATION AND CONFORMATIONAL DISEASES  
Edited by Vladimir N. Uversky and Anthony L. Fink

PROTEIN INTERACTIONS: BIOPHYSICAL APPROACHES FOR THE STUDY OF  
COMPLEX REVERSIBLE SYSTEMS  
Edited by Peter Schuck

PROTEIN MISFOLDING, AGGREGATION, AND CONFORMATIONAL DISEASES  
PART B: MOLECULAR MECHANISMS OF CONFORMATIONAL DISEASES  
Edited by Vladimir N. Uversky and Anthony L. Fink

---

A Continuation Order Plan is available for this series. A continuation order will bring delivery of each new volume immediately upon publication. Volumes are billed only upon actual shipment. For further information please contact the publisher.

# **Protein Misfolding, Aggregation, and Conformational Diseases**

## **Part B: Molecular Mechanisms of Conformational Diseases**

Edited by

**VLADIMIR N. UVERSKY**

*Department of Biochemistry and Molecular Biology, and the Center for Computational Biology and Bioinformatics, Indiana University School of Medicine, Indianapolis, Indiana; Institute for Biological Instrumentation, Russian Academy of Sciences, Pushchino, Moscow Region, Russia*

**ANTHONY L. FINK**

*Department of Chemistry and Biochemistry, University of California, Santa Cruz, California*



**Springer**

Vladimir N. Uversky  
Department of Biochemistry and Molecular Biology  
Center for Computational Biology and  
Bioinformatics  
Indiana University School of Medicine  
Indianapolis, IN 46202

Anthony L. Fink  
Department of Chemistry and Biochemistry  
University of California  
Santa Cruz, CA 95064  
USA

*and*

Institute for Biological Instrumentation  
Russian Academy of Sciences  
Pushchino, Moscow Region 142290  
Russia

Library of Congress Control Number: 2005926771

ISBN-10: 0-387-36529-X            e-ISBN-10: 0-387-36534-6  
ISBN-13: 978-0-387-36529-9       e-ISBN-13: 978-0-387-36534-3

Printed on acid-free paper

© 2007 Springer Science+Business Media, LLC

All rights reserved. This work may not be translated or copied in whole or in part without the written permission of the publisher (Springer Science+Business Media, LLC, 233 Spring Street, New York, NY 10013, USA), except for brief excerpts in connection with reviews or scholarly analysis. Use in connection with any form of information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed is forbidden.

The use in this publication of trade names, trademarks, service marks and similar terms, even if they are not identified as such, is not to be taken as an expression of opinion as to whether or not they are subject to proprietary rights.

9 8 7 6 5 4 3 2 1

springer.com

# Contents

**Contributors** ..... **xix**

## **Section I: Altered Protein Structure and Enhanced Aggregation/Deposition**

### *A $\beta$ -Protein and Alzheimer's Disease*

**1. The Pathogenesis of Alzheimer's Disease: General Overview** ..... **3**

*Liana G. Apostolova and Jeffrey L. Cummings*

Abstract	3
1.1. Introduction	3
1.2. Classification of the Proteinopathies	3
1.3. Alzheimer's Disease	5
1.3.1. Mild Cognitive Impairment as a Prodromal Stage of AD	5
1.3.2. First Stage (Early AD)	5
1.3.3. Intermediate Stage (Moderate AD)	6
1.3.4. Late Stage (Severe AD)	7
1.3.5. Variants of AD	7
1.4. Pathogenesis of AD	8
1.4.1. Protein Folding and Misfolding	8
1.4.2. Fibrillogenesis	9
1.5. Pathology of AD	10
1.5.1. $\beta$ -Amyloid	10
1.5.2. Tau	12
1.5.3. $\alpha$ -Synuclein	13
1.5.4. Synaptic Toxicity and Dysfunction	15
1.5.5. Neuronal Loss	15
1.5.6. Phenotype-Proteotype Relationship	16
1.6. Theories Behind Selective Vulnerability in AD	16
1.7. Genotype-Phenotype Relationship	18
1.8. Disease-Modifying Therapy	19
1.9. Symptomatic Therapy	20
1.10. Future Directions	20
Acknowledgments	21
References	21

<b>2. Free Radicals, Metal Ions, and A<math>\beta</math> Aggregation and Neurotoxicity .....</b>	<b>31</b>
<i>Kevin J. Barnham, Cyril C. Curtain, and Ashley I. Bush</i>	
Abstract.....	31
2.1. Introduction .....	31
2.2. APP/A $\beta$ and Metal Homeostasis .....	33
2.3. Cu <sup>2+</sup> - and Zn <sup>2+</sup> -Induced Aggregation of A $\beta$ .....	34
2.4. The Metal Binding Site(s) of A $\beta$ .....	34
2.5. A $\beta$ Redox Activity .....	37
2.6. The Effect of Metal Binding on the Interaction of A $\beta$ with Membranes .....	38
2.7. Toxic Mechanism of A $\beta$ .....	39
2.8. A $\beta$ Membrane Association and Cytotoxicity .....	40
2.9. Therapeutic Potential of Inhibiting A $\beta$ -Metal Interactions .....	41
References.....	43
 <i><math>\alpha</math>-Synuclein and Parkinson's Disease</i>	
<b>3. Progress in Understanding the Mechanisms of Neuronal Dysfunction and Degeneration in Parkinson's Disease .....</b>	<b>49</b>
<i>J. William Langston</i>	
Abstract.....	49
3.1. Introduction .....	49
3.2. Hypotheses on the Cause of Parkinson's Disease .....	50
3.3. The Discovery of the Biological Effects of MPTP .....	50
3.4. Environment and Genetic Contributions .....	51
3.5. Selective Vulnerability and Parkinson's Disease .....	52
3.6. Redefining the Parkinson's Complex .....	53
3.7. Implications for Future Research and Identifying Disease-Modifying Therapies .....	54
3.8. PARK 8: The Latest Form of Genetic Parkinsonism .....	55
3.9. Conclusion .....	55
References .....	56
<b>4. <math>\alpha</math>-Synuclein Aggregation and Parkinson's Disease .....</b>	<b>61</b>
<i>Vladimir N. Uversky</i>	
Abstract .....	61
4.1. Introduction .....	61
4.2. Structural Characteristics of Human $\alpha$ -Synuclein .....	63
4.2.1. Peculiarities of $\alpha$ -Synuclein Amino Acid Sequence .....	63
4.2.2. $\alpha$ -Synuclein is a Natively Unfolded Protein .....	64
4.2.3. Structural Consequences of Amino Acid Substitutions .....	65

4.3. Conformational Behavior of Synucleins .....	69
4.3.1. Wild-Type $\alpha$ -Synuclein .....	69
4.3.2. PD-related $\alpha$ -Synuclein Mutants .....	70
4.3.3. Studies on $\beta$ - and $\gamma$ -Synucleins .....	70
4.4. Aggregation of $\alpha$ -Synuclein and Neurodegenerative Diseases .....	70
4.4.1. Aggregation of Wild-Type Protein <i>In Vitro</i> .....	71
4.4.2. Effect of PD-Related Mutations on $\alpha$ -Synuclein Aggregation .....	72
4.4.3. Cytotoxicity of $\alpha$ -Synuclein Aggregates .....	74
4.4.4. Linking the Effect of Environmental Factors, $\alpha$ -Synuclein Aggregation, and PD .....	75
4.4.5. Effect of Oxidative Modification .....	79
4.4.6. Effect of Membranes .....	84
4.4.7. Effect of Molecular Crowding .....	84
4.4.8. Effect of Anions and Structure of Water .....	85
4.4.9. Effect of Phosphorylation .....	85
4.4.10. Effect of Sequence Truncations .....	86
4.4.11. Effect of Charged Polymers .....	87
4.4.12. Effect of Protein-Protein Interactions .....	89
4.4.13. Small Molecules Inhibiting $\alpha$ -Synuclein Fibrillation .....	92
4.5. Conclusion .....	94
Acknowledgments.....	97
References.....	97

**5. Cell Biology of  $\alpha$ -Synuclein: Implications in Parkinson's Disease and Other Lewy Body Diseases ..... 111**

*Seung-Jae Lee and Yoon Suk Kim*

Abstract .....	111
5.1. Introduction .....	111
5.2. Normal Biology .....	112
5.2.1. Identification and Expression Pattern .....	112
5.2.2. Physiologic Function .....	112
5.2.3. Degradation .....	114
5.3. Pathobiology .....	114
5.3.1. Determinants of Aggregation .....	114
5.3.2. Biochemical and Cell Biological Dissection of Aggregates .....	116
5.3.3. Effects of $\alpha$ -Syn Aggregation .....	117
5.3.4. How do Cells Handle Aggregates? .....	118
5.4. Conclusion .....	119
References.....	119



*Prion Protein and Prion Diseases*

<b>6. Pathogenesis of Prion Diseases .....</b>	<b>125</b>
<i>Giuseppe Legname, Stephen J. DeArmond, Fred E. Cohen, and Stanley B. Prusiner</i>	
Abstract .....	125
6.1. Introduction .....	125
6.1.1. Prion Biology and Diseases .....	127
6.1.2. Prion Protein and Prion Structure .....	128
6.1.3. Prion Replication .....	130
6.1.4. Transmission Barriers .....	131
6.1.5. Prion Strains .....	131
6.2. Prion Diseases of Animals .....	133
6.2.1. PrP Polymorphisms in Sheep, Cattle, and Elk .....	133
6.2.2. Bovine Spongiform Encephalopathy .....	133
6.2.3. Chronic Wasting Disease .....	134
6.3. Human Prion Diseases .....	135
6.3.1. Sporadic and Genetic Neurodegenerative Diseases: Prion Diseases .....	135
6.3.2. PrP Gene Polymorphisms and Dominant-Negative Inhibition .....	135
6.3.3. Infectious Prion Diseases .....	136
6.4. Mammalian Synthetic Prions .....	138
6.5. Conclusion .....	138
Acknowledgments.....	139
References .....	139
<b>7. Mammalian Prion Protein .....</b>	<b>147</b>
<i>Iliia V. Baskakov</i>	
Abstract .....	147
7.1. Introduction .....	147
7.2. Structural Studies of Mammalian Prion Protein .....	147
7.2.1. PrP <sup>C</sup> : Cellular Isoform of Prion Protein .....	147
7.2.2. PrP <sup>Sc</sup> : Pathologic Isoform of Prion Protein .....	148
7.3. Reconstitution of Prion Infectivity <i>In Vitro</i> .....	149
7.3.1. Amplification of PrP <sup>Sc</sup> .....	150
7.3.2. <i>In Vitro</i> Conversion of Recombinant PrP .....	150
7.3.3. Search for Cofactors Involved in Prion Replication .....	151
7.4. Kinetic Models of Prion Propagation .....	152
7.4.1. Nucleation-Polymerization and Template-Assisted Models .....	152
7.4.2. Autocatalytic Model that Uses the Mechanism of Branched-Chain Reactions .....	152
7.5. Conformational Diversity of Self-Propagating Aggregates .....	155
7.5.1. Strains of PrP <sup>Sc</sup> .....	155
7.5.2. Complexity of <i>In Vitro</i> Misfolding Pathways .....	155
7.6. Can the Prion Hypothesis Be Expanded to Non-Prion Proteins? .....	157
References.....	158

<b>8. The Yeast Prion Proteins Sup35p and Ure2p .....</b>	<b>165</b>
<i>Joanna Krzewska and Ronald Melki</i>	
Abstract .....	165
8.1. Genetic Criteria for the Prions in Yeast .....	165
8.1.1. Reversible Curability .....	165
8.1.2. The Frequency with which the Prion Phenotype Arises Increases upon Overexpression of Infectious Proteins .....	166
8.1.3. Phenotypic Relationship Between the Prion State and Mutations in the Gene of the Protein .....	166
8.2. The [PSI <sup>+</sup> ], [PIN], and [URE3] Traits .....	166
8.2.1. The [PSI <sup>+</sup> ] and [PIN] Traits .....	166
8.2.2. The [URE3] Trait .....	169
8.3. Other Potential Prions .....	170
8.4. The “Prion Domains” of Yeast Prions .....	171
8.5. Structural Features .....	171
8.6. <i>In Vitro</i> Assembly Process of Yeast Prions .....	172
8.7. Nature of the Fibrillar Forms of Sup35p and Ure2p .....	173
8.8. Mechanistic Models for Prion Propagation .....	174
8.9. Maintenance and Inheritance .....	176
8.10. Potential Role of Yeast Prions .....	177
8.11. Conclusions, Perspectives, and Limitations of <i>S. cerevisiae</i> Prions as Model Systems for Mammalian Prions and Polyglutamine Diseases .....	178
Acknowledgment .....	179
References .....	179
<b>9. Immunoglobulin Light Chain and Systemic Light-Chain Amyloidosis .....</b>	<b>183</b>
<i>Marina Ramirez-Alvarado, Janelle K. De Stigter, Elizabeth M. Baden, Laura A. Sikkink, Richard W. McLaughlin, and Anya L. Taboas</i>	
Abstract .....	183
9.1. Light-Chain Amyloidosis and Multiple Myeloma as Related Hematologic Malignancies .....	183
9.1.1. Light-Chain Amyloidosis .....	183
9.1.2. Multiple Myeloma .....	184
9.2. Immunoglobulin Light-Chain Structure .....	184
9.2.1. Crystal Structures of Amyloidogenic Light-Chain Proteins .....	186
9.3. Unique Properties of AL .....	186
9.3.1. Light-Chain Isotypes in MM and AL, Truncations, and Mutational Diversity .....	186
9.3.2. Association with Heavy Chain .....	186
9.3.3. Systemic Nature and Mortality .....	187
9.3.4. AL Organ Tropism .....	187
9.3.5. Current Therapies .....	188
9.4. Thermodynamics Studies of AL Proteins .....	188
9.4.1. Possible Causes of Instability for AL Proteins .....	188
9.4.2. Thermodynamic Stability Differences Between MM and AL Proteins .....	189

9.5. Fibril Formation Studies of AL Proteins .....	189
9.6. Recent Findings .....	191
9.6.1. Large Mutational Diversity .....	191
9.6.2. Addressing Organ Tropism by Studying the Effect of Glycosaminoglycans .....	192
9.6.3. Studying Protein Thermodynamics and Fibril Formation to Understand the Complication from MM to AL .....	192
9.6.4. Biochemical Characteristics of AL Proteins that Depend Largely on Their Mutational Diversity: Low pH is Not Always Destabilizing .....	192
9.7. Future Directions in the Study and Treatment of AL .....	194
9.7.1. Understand Mutational Diversity and Organ Tropism .....	194
9.7.2. Determine the Toxic Species in AL Pathogenesis .....	194
9.7.3. Therapeutic Approaches .....	194
References.....	195
<b>10. Pancreatic Islet Amyloid and Diabetes .....</b>	<b>199</b>
<i>Anne Clark and Jenni Moffitt</i>	
Abstract .....	199
10.1. Introduction .....	199
10.2. Islet Amyloid Polypeptide and Fibril Formation .....	201
10.2.1. Molecular Structure of IAPP and $\beta$ -Sheet Formation .....	202
10.3. Islet Amyloid and the Pathophysiology of Type 2 Diabetes .....	204
10.4. Potential Fibrillogenic Factors for IAPP .....	207
10.4.1. Where Is Amyloid Found in the Islet? .....	207
10.4.2. What Normally Prevents IAPP Conversion into Fibrils? .....	207
10.4.3. What Factors Could Destabilize Solubility of Human IAPP? .....	208
10.4.4. Genetically Determined Structural Changes: Mutations in the IAPP Gene .....	208
10.4.5. Aberrant Production of IAPP .....	209
10.4.6. IAPP Concentration .....	209
10.5. Consequences of Fibrils in Islets .....	210
10.5.1. Fibril-Induced Cell Death .....	210
10.5.2. Development of Inhibitors for Islet Amyloidosis .....	210
10.6. Conclusion .....	210
Acknowledgments .....	211
References .....	211
<b>11. <math>\beta_2</math>-Microglobulin and Dialysis-Related Amyloidosis .....</b>	<b>217</b>
<i>Isobel J. Morten, Eric W. Hewitt, and Sheena E. Radford</i>	
Abstract .....	217
11.1. Introduction .....	217
11.2. Normal Cellular Role of $\beta_2$ M .....	219
11.3. Treatments for DRA .....	220
11.4. Components of <i>Ex Vivo</i> Amyloid .....	221

11.4.1. Modifications of $\beta_2m$ in Amyloid Deposits in DRA Patients .....	221
11.4.2. Other Components of $\beta_2m$ Amyloid .....	222
11.5. Role of the Synovial Cellular Environment in DRA .....	224
11.6. Structure of $\beta_2m$ .....	225
11.6.1. MHC Class I-Associated $\beta_2m$ .....	225
11.6.2. Monomeric $\beta_2m$ .....	226
11.7. $\beta_2m$ Amyloid Fibril Formation <i>In Vitro</i> .....	227
11.7.1. $\beta_2m$ Fibrillogenesis Under Acidic Conditions .....	227
11.7.2. Regions of $\beta_2m$ Involved in Fibril Formation .....	230
11.7.3. $\beta_2m$ Fibril Formation at pH 7.0 .....	231
11.7.4. Kinetic Mechanisms of Fibril Formation <i>In Vitro</i> .....	232
11.8. Conclusion .....	232
Acknowledgments .....	233
References .....	234
<b>12. Serum Amyloid A and AA Amyloidosis .....</b>	<b>241</b>
<i>Zafer Ali-Khan</i>	
Abstract .....	241
12.1. Introduction .....	241
12.2. AA Amyloidosis .....	242
12.3. The Apolipoprotein Serum Amyloid A and AA Amyloid Protein .....	243
12.4. Regulation of Serum Amyloid A .....	244
12.5. Serum and Monocytoid Cell-Associated Pools of Serum Amyloid A .....	245
12.6. Do Murine Monocytoid Cells Possess Serum Amyloid A Receptor? .....	247
12.7. Metabolism of Serum Amyloid A: Role of Lysosomal Cathepsins .....	248
12.8. Proinflammatory Functions of Serum Amyloid A .....	249
12.9. Possible Links Among Oxidative Stress, Defective Intralysosomal Serum Amyloid A Metabolism, and Nascent AA Fibril Formation .....	250
12.10. Conclusion .....	251
Acknowledgments .....	251
References .....	251

**Section II: Point Mutations and Enhanced Protein Deposition**

<b>13. Transthyretin and the Transthyretin Amyloidoses .....</b>	<b>259</b>
<i>Joel N. Buxbaum</i>	
Abstract .....	259
13.1. Introduction .....	259
13.1.1. The Transthyretin Gene .....	260
13.1.2. TTR Expression .....	261
13.1.3. TTR Function .....	263
13.1.4. TTR in Plasma .....	264
13.1.5. TTR in the Cerebrospinal Fluid .....	265
13.1.6. Transthyretin, the Protein .....	265

13.2. TTR and Human Disease .....	266
13.2.1. Plasma TTR as a Marker of Nutritional Status .....	266
13.2.2. The TTR Amyloidoses as Disorders of Protein Conformation .....	267
13.2.3. <i>In Vitro</i> Analyses .....	267
13.2.4. Transthyretin Amyloidosis .....	269
13.2.5. The Relationship Between Specific Mutations and Clinical Disease .....	269
13.2.6. Age of Onset .....	272
13.2.7. Environmental Effects .....	272
13.2.8. Wild-Type TTR Deposition .....	273
13.2.9. Experimental Models .....	274
13.2.10. Cell Culture Models .....	275
13.2.11. Treatment of the Human TTR Amyloidoses .....	276
References .....	277
<b>14. Human Lysozyme .....</b>	<b>285</b>
<i>Mireille Dumoulin, Russell J.K. Johnson, Vittorio Bellotti, and Christopher M. Dobson</i>	
Abstract .....	285
14.1. Introduction .....	285
14.2. Lysozyme Amyloidosis .....	287
14.3. <i>In Vitro</i> Studies of the Properties of the Variant Lysozymes .....	289
14.3.1. Wild-Type Lysozyme and Its Amyloidogenic Variants Can Form Amyloid Fibrils <i>In Vitro</i> .....	289
14.3.2. The Variant Proteins Have a Native Fold Similar to that of the Wild-Type Protein .....	290
14.3.3. Effects of the Mutations on the Stability and Folding of Lysozyme .....	295
14.3.4. Effects of the Mutations on the Dynamic Properties of the Native State of Lysozyme .....	297
14.4. Mechanism of Amyloid Fibril Formation .....	298
14.5. Inhibition of Amyloid Fibril Formation .....	302
14.6. Conclusion .....	304
Acknowledgments .....	305
References .....	305
<b>15. Serpins and the Diversity of Conformational Diseases .....</b>	<b>309</b>
<i>Robin W. Carrell</i>	
Abstract .....	309
15.1. Introduction .....	309
15.1.1. What is a Conformational Disease? .....	310
15.1.2. Aggregation Rather Than Amyloid .....	310
15.1.3. Gain-of-Function Disadvantage .....	311

15.2. The Serpins .....	311
15.2.1. Mobility and Vulnerability .....	311
15.2.2. Mutations and Disease .....	314
15.2.3. Monomers, Oligomers, and $\beta$ -Promiscuity .....	314
15.2.4. Latent Antithrombin, Propagation, and Prions .....	315
15.2.5. $\alpha$ 1-Antitrypsin and Hepatocellular Toxicity .....	315
15.2.6. ER Aggregation and the Neuroserpin Dementias .....	316
15.3. What Causes Cell Toxicity? .....	317
15.4. Are Oligomers Toxic? .....	318
15.4.1. Oligomer Infectivity .....	318
15.4.2. Implications for Treatment .....	319
15.5. Conclusion: Why “Conformational Diseases”? .....	320
References .....	321

**Section III: Altered Protein Structure and Impaired Function**

**16. Human Copper-Zinc Superoxide Dismutase and Familial Amyotrophic Lateral Sclerosis ..... 327**

*Ahmad Galaleldeen and P. John Hart*

Abstract .....	327
16.1. Amyotrophic Lateral Sclerosis .....	327
16.2. SOD1 Structure and Enzymatic Activity .....	328
16.3. SOD1 and Toxic Gain-of-Function .....	329
16.3.1. Pathogenic SOD1 Aggregation .....	330
16.3.2. Impairment of Proteasome Activity in ALS .....	331
16.4. Classification of SOD1 Mutants .....	331
16.5. Negative Design of Wild-Type SOD1 .....	332
16.6. Models of SOD1 Self-Association .....	333
16.6.1. Dimer Models of Aggregation .....	333
16.6.2. Monomer Model of Pathogenic SOD1 Aggregation .....	336
16.7. Oxidative Damage and Models of Aggregation .....	339
16.8. Therapeutic Approaches for ALS .....	341
Acknowledgments .....	341
References .....	341

**17. Understanding the Effects of Cancer-Associated Mutations in the Tumor Suppressor Protein p53: Structural Consequences of Mutations and Possible Ways of Rescuing Oncogenic Mutants ..... 345**

*Andreas C. Joerger, Assaf Friedler, and Alan R. Fersht*

Abstract .....	345
17.1. Introduction .....	345
17.2. The Domain Structure of Human p53 .....	346

17.3. The Crystal Structure of the DNA-Binding Domain .....	348
17.4. The Consequences and Effects of p53 Mutations at the Molecular Level .....	348
17.4.1. Effect of Mutations on Stability .....	349
17.4.2. Design of a Superstable p53 Core Domain Mutant .....	350
17.4.3. Crystal Structure of the Superstable p53 Core Domain Mutant ( <i>T</i> -p53C) ...	351
17.4.4. Structural Effects of Destabilizing Mutations in p53 Core Domain .....	353
17.5. Reversing the Structural Effects of p53 Mutations with Small Molecules .....	354
17.5.1. Kinetic Instability of p53 Core Domain Mutants .....	354
17.5.2. Search for Small-Molecule Chemical Chaperones that Stabilize p53 Core Domain .....	355
17.5.3. CDB3: A Chemical Chaperone that Binds and Stabilizes Mutant p53 <i>In Vitro</i> and <i>In Vivo</i> .....	356
17.6. Reversing the Structural Effects of Tumorigenic Mutations by Second-Site Suppressor Mutations .....	356
17.6.1. Insights into the Mechanism of Rescue .....	358
17.7. Conclusion .....	359
References .....	359

## Section IV: Changes in Supramolecular Structure

<b>18. Protein Aggregation in Muscle Fibers and Respective Neuromuscular Disorders .....</b>	<b>365</b>
<i>Alexandra Vrabie and Hans H. Goebel</i>	
Abstract .....	365
18.1. Introduction .....	365
18.2. Actinopathies .....	366
18.2.1. Actin .....	367
18.2.2. Genetics .....	367
18.2.3. Clinical Features .....	368
18.2.4. Morphologic Features .....	368
18.3. Myosinopathies .....	370
18.3.1. Myosin .....	370
18.3.2. Genetics .....	370
18.3.3. Clinical Features .....	371
18.3.4. Morphologic Features .....	371
18.4. Desminopathies .....	372
18.4.1. Desmin .....	372
18.4.2. Genetics .....	373
18.4.3. Clinical Features .....	373
18.4.4. Morphologic Features .....	374
18.5. Inflammatory and Hereditary Inclusion Body Myopathies .....	378
18.5.1. Inclusion Bodies .....	378
18.5.2. Genetics .....	379
18.5.3. Clinical Features .....	379
18.5.4. Morphologic Features .....	379